Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Skyline Medical, a Division of Predictive Oncology Inc. (POAI), Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
  Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY .   The STREAMWAY System transforms the collection, measurement and disposal of healthcare waste fluid making it safer, easier and environmentally
View HTML
Toggle Summary Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock
MINNEAPOLIS, Minn. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced the pricing of its previously announced public offering of its common stock, with anticipated gross proceeds of up to $3,167,768.50 , before deducting
View HTML
Toggle Summary Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
  Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY .   The STREAMWAY System transforms the collection, measurement and disposal of healthcare waste fluid making it safer, easier and environmentally
View HTML
Toggle Summary Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock
MINNEAPOLIS , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the
View HTML
Toggle Summary Predictive Oncology Inc. Announces Repayment or Extension of Promissory Notes due September 28, 2019
MINNEAPOLIS , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019 , the Company repaid the remaining
View HTML
Toggle Summary Coverage Initiated for Predictive Oncology via NetworkNewsWire
NEW YORK , Sept. 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative company focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcome, today announces it has selected the corporate
View HTML
Toggle Summary Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 5:30PM Today MINNEAPOLIS , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional
View HTML
Toggle Summary Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019
Conference Call to be held August 19, 2019, at 4:30pm Eastern Time MINNEAPOLIS , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the
View HTML
Toggle Summary Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India
MINNEAPOLIS , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals.
View HTML
Toggle Summary Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models
Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS , July 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a
View HTML